DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective

A Pathak, A Rohilla, T Gupta, MJ Akhtar… - European Journal of …, 2018 - Elsevier
Alzheimer, the fourth leading cause of death embodies a key responsible event including
formation of β-amyloid protein clustering to amyloid plaque on blood vessels. The origin of …

DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease

MM de Souza, AR Cenci, KF Teixeira… - Current Medicinal …, 2023 - ingentaconnect.com
Background: Alzheimer's disease (AD) is a chronic neurodegenerative disease and the most
common form of dementia, especially in the elderly. Due to the increase in life expectancy, in …

Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

B Smith, F Medda, V Gokhale… - ACS chemical …, 2012 - ACS Publications
With 24.3 million people affected in 2005 and an estimated rise to 42.3 million in 2020,
dementia is currently a leading unmet medical need and costly burden on public health …

DYRK1A inhibitors for disease therapy: Current status and perspectives

T Liu, Y Wang, J Wang, C Ren, H Chen… - European journal of …, 2022 - Elsevier
Dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A) is a conserved
protein kinase that plays essential roles in various biological processes. It is located in the …

DYRK1A inhibition as potential treatment for Alzheimer's disease

S Stotani, F Giordanetto, F Medda - Future medicinal chemistry, 2016 - Taylor & Francis
In total, 47,500,000 people worldwide are affected by dementia and this number is estimated
to double by 2030 and triple within 2050 resulting in a huge burden on public health …

DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications

R Abbassi, TG Johns, M Kassiou, L Munoz - Pharmacology & therapeutics, 2015 - Elsevier
Protein kinases are one of the most studied drug targets in current pharmacological
research, as evidenced by the vast number of kinase-targeting agents enrolled in active …

[b]-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors

C Lechner, M Flaßhoff, H Falke, L Preu, N Loaëc… - Molecules, 2019 - mdpi.com
Since hyperactivity of the protein kinase DYRK1A is linked to several neurodegenerative
disorders, DYRK1A inhibitors have been suggested as potential therapeutics for Down …

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors as potential therapeutics

DB Jarhad, KK Mashelkar, HR Kim… - Journal of medicinal …, 2018 - ACS Publications
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a member of an
evolutionarily conserved family of protein kinases that belongs to the CMGC group of …

Development of novel 2, 4-bispyridyl thiophene–based compounds as highly potent and selective Dyrk1A inhibitors. Part I: benzamide and benzylamide derivatives

SS Darwish, M Abdel-Halim, M Salah, AH Abadi… - European Journal of …, 2018 - Elsevier
The protein kinase Dyrk1A modulates several processes relevant to the development or
progression of Alzheimer's disease (AD), eg through phosphorylation of tau protein, amyloid …

Recent research and development of DYRK1A inhibitors

L Zhao, X Xiong, L Liu, Q Liang, R Tong, X Feng… - Chinese Chemical …, 2022 - Elsevier
Dual specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) is an evolutionarily
conserved protein kinase belonging to the CMGC kinase family, which is closely related to …